SH-110, a liquid cancer treatment for glioma, earned orphan drug status from the FDA, helping patients who struggle to ...

Company Set to Make Migration from Preclinical to Clinical Stage BALTIMORE, MD / ACCESS Newswire / July 17, 2025 / Goldman ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials.

The antibody anselamimab, which AstraZeneca picked up in its 2021 purchase of Caelum Biosciences, failed to improve survival ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to a new gene therapy for Amyotrophic Lateral ...

The FDA designates SH-110 as an orphan drug, offering a safer oral treatment option for glioma patients with swallowing ...

KLTO‑202 is an experimental gene therapy that would deliver the instructions for a protein that may reduce inflammation and ...

Important near-term catalysts for ETON have been eliminated due to insider stock sales and a disappointing partial FDA ...

Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for SH-110, a ...